T1	Participants 202 224	adolescent migraineurs
T2	Participants 286 313	Patients aged 12 to 17 year
T3	Participants 372 435	for a moderate or severe headache and for up to two recurrences
T4	Participants 324 371	rizatriptan 5 mg (n = 149) or placebo (n = 147)
